Matteo Stravalaci

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5094049/publications.pdf

Version: 2024-02-01

45	2,308	279798 23	265206 42
papers	citations	h-index	g-index

50	50	50	3983
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synthetic amyloid-Î² oligomers impair long-term memory independently of cellular prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2295-2300.	7.1	435
2	Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis. Journal of Immunology, 2011, 187, 172-180.	0.8	220
3	An N-terminal Fragment of the Prion Protein Binds to Amyloid-Î² Oligomers and Inhibits Their Neurotoxicity in Vivo. Journal of Biological Chemistry, 2013, 288, 7857-7866.	3.4	162
4	An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. Journal of Experimental Medicine, 2015, 212, 905-925.	8.5	128
5	The Long Pentraxin PTX3 as a Link Between Innate Immunity, Tissue Remodeling, and Cancer. Frontiers in Immunology, 2019, 10, 712.	4.8	125
6	Targeting Mannose-Binding Lectin Confers Long-Lasting Protection With a Surprisingly Wide Therapeutic Window in Cerebral Ischemia. Circulation, 2012, 126, 1484-1494.	1.6	119
7	Recombinant C1 inhibitor in brain ischemic injury. Annals of Neurology, 2009, 66, 332-342.	5.3	107
8	Clusterin Binds to AÎ²1â€“42 Oligomers with High Affinity and Interferes with Peptide Aggregation by Inhibiting Primary and Secondary Nucleation. Journal of Biological Chemistry, 2016, 291, 6958-6966.	3.4	99
9	Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules. Nature Immunology, 2022, 23, 275-286.	14.5	95
10	The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cellâ€“mediated resistance to metastasis. Nature Immunology, 2019, 20, 1012-1022.	14.5	75
11	Non-peptidic Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors. Journal of Biological Chemistry, 2010, 285, 8733-8742.	3.4	70
12	Applications of Surface Plasmon Resonance (SPR) for the Characterization of Nanoparticles Developed for Biomedical Purposes. Sensors, 2012, 12, 16420-16432.	3.8	59
13	Specific Recognition of Biologically Active Amyloid-Î² Oligomers by a New Surface Plasmon Resonance-based Immunoassay and an in Vivo Assay in Caenorhabditis elegans. Journal of Biological Chemistry, 2012, 287, 27796-27805.	3.4	52
14	A modified protocol to prepare seed-free starting solutions of amyloid-Î² (AÎ²)1â€“40 and AÎ²1â€“42 from the corresponding depsipeptides. Analytical Biochemistry, 2011, 411, 297-299.	2.4	38
15	Use of surface plasmon resonance to study the elongation kinetics and the binding properties of the highly amyloidogenic AÎ²1â€“42 peptide, synthesized by depsi-peptide technique. Biosensors and Bioelectronics, 2011, 26, 2772-2775.	10.1	36
16	TNF-Stimulated Gene-6 Is a Key Regulator in Switching Stemness and Biological Properties of Mesenchymal Stem Cells. Stem Cells, 2019, 37, 973-987.	3.2	36
17	Pharmacological inhibition of mannose-binding lectin ameliorates neurobehavioral dysfunction following experimental traumatic brain injury. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 938-950.	4.3	35
18	A cationic tetrapyrrole inhibits toxic activities of the cellular prion protein. Scientific Reports, 2016, 6, 23180.	3.3	34

#	Article	IF	Citations
19	Interaction of C1q With Pentraxin 3 and IgM Revisited: Mutational Studies With Recombinant C1q Variants. Frontiers in Immunology, 2019, 10, 461.	4.8	32
20	Good gene, bad gene: New APP variant may be both. Progress in Neurobiology, 2012, 99, 281-292.	5.7	31
21	Expression of A2V-mutated AÎ² in Caenorhabditis elegans results in oligomer formation and toxicity. Neurobiology of Disease, 2014, 62, 521-532.	4.4	30
22	Exploring the role of MKK7 in excitotoxicity and cerebral ischemia: a novel pharmacological strategy against brain injury. Cell Death and Disease, 2015, 6, e1854-e1854.	6.3	29
23	Fingolimod Limits Acute AÎ² Neurotoxicity and Promotes Synaptic Versus Extrasynaptic NMDA Receptor Functionality in Hippocampal Neurons. Scientific Reports, 2017, 7, 41734.	3.3	27
24	Humanin Specifically Interacts with Amyloid-Î² Oligomers and Counteracts Their in vivo Toxicity. Journal of Alzheimer's Disease, 2017, 57, 857-871.	2.6	23
25	Differential expression and regulation of MS4A family members in myeloid cells in physiological and pathological conditions. Journal of Leukocyte Biology, 2022, 111, 817-836.	3.3	23
26	An antipsychotic drug exerts anti-prion effects by altering the localization of the cellular prion protein. PLoS ONE, 2017, 12, e0182589.	2.5	19
27	The new Î² amyloid-derived peptide AÎ²1â€“6A2V-TAT(D) prevents AÎ² oligomer formation and protects transgenic C. elegans from AÎ² toxicity. Neurobiology of Disease, 2016, 88, 75-84.	4.4	17
28	Immunopurification of Pathological Prion Protein Aggregates. PLoS ONE, 2009, 4, e7816.	2.5	17
29	A New Surface Plasmon Resonance-Based Immunoassay for Rapid, Reproducible and Sensitive Quantification of Pentraxin-3 in Human Plasma. Sensors, 2014, 14, 10864-10875.	3.8	16
30	Novel approaches for studying amyloidogenic peptides/proteins. Current Opinion in Pharmacology, 2013, 13, 797-801.	3.5	15
31	New insights into the molecular mechanisms underlying sensitivity/resistance to the atypical retinoid ST1926 in acute myeloid leukaemia cells: The role of histone H2A.Z, cAMP-dependent protein kinase A and the proteasome. European Journal of Cancer, 2013, 49, 1491-1500.	2.8	14
32	Epitope scanning indicates structural differences in brain-derived monomeric and aggregated mutant prion proteins related to genetic prion diseases. Biochemical Journal, 2013, 454, 417-425.	3.7	12
33	The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-Î² Oligomers. Journal of Alzheimer's Disease, 2016, 53, 1485-1497.	2.6	12
34	Control of Complement Activation by the Long Pentraxin PTX3: Implications in Age-Related Macular Degeneration. Frontiers in Pharmacology, 2020, 11, 591908.	3.5	11
35	A New Surface Plasmon Resonance Assay for In Vitro Screening of Mannose-Binding Lectin Inhibitors. Journal of Biomolecular Screening, 2016, 21, 749-757.	2.6	9
36	Where Are We with RPE Replacement Therapy? A Translational Review from the Ophthalmologist Perspective. International Journal of Molecular Sciences, 2022, 23, 682.	4.1	9

#	Article	IF	Citations
37	The Long Pentraxin PTX3 Controls Klebsiella Pneumoniae Severe Infection. Frontiers in Immunology, 2021, 12, 666198.	4.8	8
38	The Long Pentraxin PTX3 as a New Biomarker and Pharmacological Target in Age-Related Macular Degeneration and Diabetic Retinopathy. Frontiers in Pharmacology, 2021, 12, 811344.	3.5	8
39	Functional analysis of a murine monoclonal antibody against the repetitive region of the fibronectin-binding adhesins fibronectin-binding proteinâ€ƒA and fibronectin-binding proteinâ€ƒB from Staphylococcusâ€ƒaureus. FEBS Journal, 2010, 277, 4490-4505.	4.7	7
40	Scaffold Optimisation of Tetravalent Antagonists of the Mannose Binding Lectin. Chemistry - A European Journal, 2016, 22, 3686-3691.	3.3	7
41	Reply to: HultstrÃ¶m et al., Genetic determinants of mannose-binding lectin activity predispose to thromboembolic complications in critical COVID-19. Mannose-binding lectin genetics in COVID-19. Nature Immunology, 2022, 23, 865-867.	14.5	4
42	Mannose binding lectin as a target for cerebral ischemic injury. Molecular Immunology, 2011, 48, 1677.	2.2	2
43	Targeting MBL in cerebral ischemia induces long lasting protection with a wide therapeutic window. Immunobiology, 2012, 217, 1207.	1.9	0
44	P3-068: CLUSTERIN REDUCES THE FORMATION OF BIOLOGICAL RELEVANT TOXIC SOLUBLE ABETA1-42 OLIGOMERS. , 2014, 10, P651-P652.		0
45	An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. Journal of Cell Biology, 2015, 209, 2094OIA93.	5.2	0